 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || ADI-001 / Adicet Bio
Trial completion date, Trial primary completion date: GLEAN-1: A Phase 1 Study of ADI-001 in B Cell Malignancies (clinicaltrials.gov) - Apr 10, 2024
P1, N=78, Recruiting, Sponsor: Adicet Bio, Inc
Trial completion date: Mar 2024 --> Dec 2027 | Trial primary completion date: Mar 2023 --> Dec 2025
- ADI-001 / Adicet Bio
Validation of a Vector Copy Number (VCN) Digital Droplet (dd) PCR Test for the Detection of Anti-CD20 CAR T Cells in the Phase 1 Clinical Trial of ADI-001 () - Mar 14, 2024 - Abstract #TRICON2024TRICON_17;
- ADI-001 / Adicet Bio
Expansion, Persistence and Pharmacodynamic Profile of ADI-001, a First-in-Class Allogeneic CD20-Targeted CAR Gamma Delta T Cell Therapy, in Patients with Relapsed/Refractory Aggressive B-Cel... (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_4423;
P1
ADI-001 C max and D28 persistent exposure were comparable to, or exceeded, those demonstrated by alternative allogeneic CAR T therapies and approved autologous CD19 CAR T therapies. Favorable clinical responses were also associated with higher mean and median peak of ADI-001 cells.
- ADI-001 / Adicet Bio
Assay development and quantitative detection of ADI-001, a CD20-targeted ??1 CAR T therapy, using AlloCell, a universal assay for monitoring of off-the-shelf allogeneic cell therapies (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_1018;
P1
Conclusions AlloCell was validated as a precise and sensitive analytical platform that can quantitatively monitor PK of allogeneic cell therapies. Application of AlloCell to monitor clinical exposure of ADI-001 successfully demonstrated dose-dependent expansion and persistence across multiple dose levels and resolved donor origin for distinct ADI-001 expansions associated with a multiple dosing regimen.
- |||| ADI-001 / Adicet Bio
Dr. Neelapu showing spectacular data including in the CD19 CAR-exposed population: A Phase 1 Study of ADI-001: Anti-CD20 CAR-Engineered Allogeneic Gamma Delta1 (γδ) T Cells in Adults with B-Cell Malignancies #tandem23 https://t.co/0Eg1ehlEnD #TcellRx (Twitter) - Feb 15, 2023
- ||||||| ADI-001 / Adicet Bio
Clinical, P1 data, CAR T-Cell Therapy, Cytokine release syndrome: Sattva Neelapu @MDAndersonNews discusses first in human data with allogeneic gamma/delta CD20 #CARTcells ADI-001 in #lymphoma @ASTCT @CIBMTR 75% ORR 69% CR No #GVHD or grade 3/4 CRS or ICANS. 100% CR in 5 pts with LBCL after prior CD19 CAR T therapy #Tandem23 (Twitter) - Feb 15, 2023
- | ADI-001 / Adicet Bio
#Ash2022: #Adicet 社のデジャヴ #他家γδCART #ADI001 の小規模試験への期待が掛かっている中、現在16名のリンパ腫の被験者を含むデータでは、他の他家細胞治療企業と同様に、再発が問題となっている。 https://t.co/spCmvLROdC #Evaluate (Twitter) - Dec 20, 2022
- ADI-001 / Adicet Bio
A Phase 1 Study of ADI-001: Anti-CD20 CAR-Engineered Allogeneic Gamma Delta1 (γδ) T Cells in Adults with B-Cell Malignancies (World Center Marriott Royal; In-Person) - Dec 16, 2022 - Abstract #TCTASTCTCIBMTR2023TCT_ASTCT_CIBMTR_656;
Preliminary efficacy showed encouraging CR rate and sustained durability in patients, including those previously exposed to CAR T therapy. Additional data will be presented at the meeting.
- || ADI-001 / Adicet Bio
Here's the updated $ACET swimmers plot for ADI-001. 5 Dec cutoff, just press released and not at #ASH22. n=16, best ORR 75%, falling to 18% at 6mth. (Twitter) - Dec 10, 2022
- ADI-001 / Adicet Bio
A Phase 1 Study of ADI-001: Anti-CD20 CAR-Engineered Allogeneic Gamma Delta1 (γδ) T Cells in Adults with B-Cell Malignancies (Hall D (Ernest N. Morial Convention Center)) - Nov 4, 2022 - Abstract #ASH2022ASH_2887;
Preliminary efficacy showed encouraging CR rate and sustained durability in patients, including those previously exposed to CAR T therapy. Additional data will be presented at the meeting.
- |||| ADI-001 / Adicet Bio
CAR T-Cell Therapy: When we look at the totality of these early data, we have an indicator that allogeneic gamma-delta CAR T cell therapy like ADI-001 could be a significant advance. https://t.co/dQ87JItZEn (Twitter) - Jun 7, 2022
- | ADI-001 / Adicet Bio
Note: higher ADI-001 dose level 4 has been added $ACET #ASCO22 (Twitter) - Jun 6, 2022
- || ADI-001 / Adicet Bio
S Neelapu on $ACET ADI-001 #ASCO22 (Twitter) - Jun 6, 2022
- ADI-001 / Adicet Bio
A phase 1 study of ADI-001: Anti-CD20 CAR-engineered allogeneic gamma delta (γδ) T cells in adults with B-cell malignancies. (Available On Demand) - Apr 28, 2022 - Abstract #ASCO2022ASCO_5892;
P1
ADI-001 γδ CAR T cells were well tolerated, with a favorable safety profile and encouraging preliminary efficacy. Patients who achieved CR at day 28 appeared to be disease free during further follow-up at month-3.
- | ADI-001 / Adicet Bio
Preclinical, Journal: Allogeneic CD20-targeted γδ T cells exhibit innate and adaptive antitumor activities in preclinical B-cell lymphoma models. (Pubmed Central) - Feb 10, 2022
P1
Furthermore, CD20 CAR Vδ1 γδ T cells did not induce xenogeneic graft-versus-host disease in immunodeficient mice. These preclinical data support the clinical evaluation of ADI-001, an allogeneic CD20 CAR Vδ1 γδ T cell, and a phase 1 study has been initiated in patients with B-cell malignancies (NCT04735471).
- ADI-001 / Adicet Bio
A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-Engineered Allogeneic Gamma Delta (γδ) T Cells in Adults with B Cell Malignancies, in Monotherapy and Combination with IL-2 (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_4479;
P1
The secondary objectives for Parts 1, 2 and 3 include PK, immunogenicity, and antitumor activity of ADI-001 monotherapy or in combination with IL-2. This study is currently enrolling in 4 U.S. sites (NCT04735471).
- ||| ADI-001 / Adicet Bio
Enrollment open, CAR T-Cell Therapy: Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells (clinicaltrials.gov) - Aug 31, 2021
P=N/A, N=50, Enrolling by invitation, Sponsor: Adicet Bio, Inc
This study is currently enrolling in 4 U.S. sites (NCT04735471). Not yet recruiting --> Enrolling by invitation
- | ADI-001 / Adicet Bio
Journal: Efficient Genetic Transformation and Regeneration of a Farmer-Preferred Cassava Cultivar From Ghana. (Pubmed Central) - Jun 22, 2021
We show that using flow cytometry for analysis of nuclear ploidy in FEC tissues prior to genetic transformation ensures the selection of genetically uniform FEC tissue for transformation. The high percentage of single insertion events in transgenic lines indicates the suitability of the ADI 001 cultivar for the introduction of virus resistance and other useful agronomic traits into the farmer-preferred cassava germplasm in Ghana and Africa.
- |||||| ADI-001 / Adicet Bio
New trial, CAR T-Cell Therapy: Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells (clinicaltrials.gov) - Jun 3, 2021
P, N=50, Not yet recruiting, Sponsor: Adicet Bio, Inc
- ||| ADI-001 / Adicet Bio
Enrollment open, Monotherapy: GLEAN-1: A Phase 1 Study of ADI-001 in B Cell Malignancies (clinicaltrials.gov) - Mar 7, 2021
P1, N=76, Recruiting, Sponsor: Adicet Bio, Inc
The high percentage of single insertion events in transgenic lines indicates the suitability of the ADI 001 cultivar for the introduction of virus resistance and other useful agronomic traits into the farmer-preferred cassava germplasm in Ghana and Africa. Not yet recruiting --> Recruiting
- | ADI-001 / Adicet Bio
New P1 trial, Monotherapy: GLEAN-1: A Phase 1 Study of ADI-001 in B Cell Malignancies (clinicaltrials.gov) - Feb 3, 2021
P1, N=76, Not yet recruiting, Sponsor: Adicet Bio, Inc